Terminated
NCT02930161 Runihol in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome
See Trial Locations
About Locations Results Contact Us

Please note, some trial-specific information on this page is sourced from clinicaltrials.gov.

About

Trial summary
TYPE INTERVENTIONAL
PHASE
Alternative text for Phase image

Phase

Clinical trials are done in different phases (0-4). Each phase provides important information about the drug. If a drug does not pass a particular phase, it cannot progress to the next phase. Visit the About Clinical Trials page to learn more.

PHASE2
CONDITION
  • Non-alcoholic Fatty Liver Disease
    • INTERVENTIONS
    Interventions tooltip icon

    Interventions

    The drug, device, or procedure being tested.

      DRUG:Runihol
      Composition of Runihol®: One tablet contains: Active ingredients: succinic acid - 0.250 g; Riboxinum (inosine) - 0.100 g; taurine - 0.050 g; Methionine - 0.050 g Excipients - 0.184 g: potato starch, povidone, microcrystalline cellulose, calcium stearate, hypromellose, polysorbate-80. Enteric coat - 0.061 g: methacrylic acid-ethyl acrylate copolymer, talc, titanium dioxide, triethyl citrate, colloidal silicon dioxide, sodium hydrogencarbonate, sodium lauryl sulfate.
      OTHER:Placebo
      The composition of the drug in one tablet: Active substance: None. The tablet core - 0.634 g: potato starch, povidone, microcrystalline cellulose, calcium stearate, hypromellose, polysorbate-80. Enteric coat - 0.061 g: methacrylic acid-ethyl acrylate copolymer, talc, titanium dioxide, triethyl citrate, colloidal silicon dioxide, sodium hydrogencarbonate, sodium lauryl sulfate. Tablet weight enteric coated - 0.695 g
    ENROLLMENT
    Icon tooltip

    Enrollment

    The number of participants needed to take part in this trial.

    35 participants
    (ACTUAL)
    18 Years to 65 Years
    (ADULT, OLDER ADULT)
    LOCATIONS 3
    Key dates
    Alternative text for Keydates image

    Key dates

    When the trial is conducted - from the date the first participant is enrolled to the date of the last participants's final visit.

    May 30, 2016
    Trial start date
    October 10, 2018
    Trial end date
    More Information
    OTHER STUDY IDs
      RUN-II-2015
    Clinical Trials Gov ID NCT02930161
    Last Updated February 08, 2019
    See Trial Locations
    Resources for You
    No Matching Site found.

    We are currently unable to share site locations for this clinical trial. Please use the link to view (or find) site locations:

     CLINICALTRIALS.GOV

    Results

    The results of this clinical trial may not be available, especially if the clinical trial has not completed.

    We're committed to sharing information about our clinical research in alignment with global legal requirements, the industry trade association principles, and internal company policies. Generally, results summaries for clinical trials in approved products are available within one year of the trial completion. Please refer to Biogen's transparency & data sharing policy for more information.
    Clinical trial registers

    Clinical trial registers, like clinicaltrials.gov, provide information about registered clinical trials. 

     

    Publishing results for completed clinical trials on clinical trial registers help us share information about our clinical research. The results we publish here are written for healthcare professionals.

    CLINICALTRIALS.GOV
    Contact Us

    Please contact a clinical trial site directly to learn more about the trial. If no contact details are available, or for general inquiries, please contact the Biogen Clinical Trial Center.

    United States Biogen Clinical Trial Center

    866-633-4636

    clinicaltrials@biogen.com
    Find a trial location